✦ LIBER ✦

1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours

✍ Scribed by L.R. Molife; S. Minton; J. Vitfell-Pedersen; E. Chen; D. Sullivan; L. Yan; A.M. Zernhelt; L. Siu; J.S. de Bono; A.W. Tolcher

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 trial of the oral AKT inhibitor

✍ L Rhoda Molife,Li Yan,Joanna Vitfell-Rasmussen… 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 389 KB

Phase I/II study of DHA–paclitaxel in co

✍ Harries, M; O'Donnell, A; Scurr, M; Reade, S; Cole, C; Judson, I; Greystoke, A; 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 88 KB

Phase I clinical and pharmacokinetic stu

✍ Bahleda, Rastislav; Sessa, Cristiana; Del Conte, Gianluca; Gianni, Luca; Capri, 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 846 KB

A phase I clinical and pharmacokinetic s

✍ Miguel Angel Izquierdo; Margarita García; José Luis Pontón; Marisa Martínez; Vic 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB

A phase I study of the safety and pharma

✍ Lassen, U; Molife, L R; Sorensen, M; Engelholm, S-A; Vidal, L; Sinha, R; Penson, 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 316 KB

A phase 1 study evaluating the combinati

✍ Hudis, Clifford; Swanton, Charles; Janjigian, Yelena Y; Lee, Ray; Sutherland, St 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 622 KB